The in vivo toxicity profiles in mice and the antitumour activity in tumour bearing mice were screened for four di-n-butyltin and five triorganotin carboxylates, di-n-butyltin diterebate (5), bis(phenylacetate) (6), bis(deoxycholate) (7), bis(lithocholate) (8), tri-n-butyltin terebate (9), cinnamate (10), and triphenyltin terebate (11). At their maximum tolerated dosis (MTD), no antitumour effect (T/C .-1) was observed for the compounds 5, 7, 9, 10 and 11. The compounds 6 (T/C 0.51) and 8 (T/C 0.42) showed clear antitumour activity after single dose administration and might therefore be of interest for further antitumour activity studies.
Introduction
Organotin carboxylates often exhibit significant in vitro antitumour activities (Bou&lam, 1992) (Bou&lam, 1993) (Gielen, 1996a) (Gielen, 1996b) (Gielen, 1996c) . The in vivo toxicity profiles in mice and the antitumour activity in tumour bearing mice (Gielen, 1995) were screened for four din-butyltin carboxylates, di-n-butyltin bis(2,4-dihydroxybenzoate) (1), bis(2,5-dihydroxybenzoate) (2), bis(pentafluorophenylacetate) (3), and bis[di-n-butyl(pentafluorophenylacetato)tin] oxide (4) (Gielen, 1996d) .
All compounds revealed similar in vitro chemosensitivities in two cell lines, C26-10 and C26-A, two murine undifferentiated colon carcinoma cell lines. With all compounds tested, not only cell growth was inhibited in vitro, but also cell kill was achieved. At their maximum tolerated dose (MTD), 1 and 4 were inactive in vivo against colon 26 tumours in Balb/C mice whereas compounds 2 and 3 showed slight in vivo antitumour activity. However, the cut-off level for the growth delay factor (GDF) (>1) was not reached. With the exception of 2 administered with a single dose and 3 with the 2 doses protocol, treatment with these compounds did not increase the life span of all mice. Repeated administration of compound 2 did not improve the antitumour activity compared to single dose administration.
An additional set of compounds, active in vitro, four di-n-butyltin and five triorganotin carboxylates, namely di-n-butyltin diterebate (5) (Gielen, 1997) , bis(phenylacetate) (6), bis(deoxycholate) (7) (Willem, 1997a) , bis(lithocholate) (8) (Willem, 1997a) , tri-n-butyltin terebate (9) (Gielen, 1997) , cinnamate (10) (Willem, 1997b) , and triphenyltin terebate (11) (Gielen, 1997) , were subjected to further investigations. In vivo toxicity and antitumour screening results are presented.
Materials and Methods
The structures of the seven compounds screened are depicted in figure 1. Their synthesis and characterization were described earlier (Gielen, 1997) (Willem, 1997a) (Willem, 1997b) .
Toxicity and in vivo screening. The experimental procedure was described earlier (Gielen, 1996d) . The test compounds were dissolved in DMSO to a concentration ranging from 50 to 100 mg/ml and diluted to 10 mg/ml in arachidis oil, which was also used for further dilutions. Occasionally the DMSO had to be acidified or made alkaline to get a clear solution. The amount of DMSO could not be increased since mice do not tolerate more than 1%. Mice were injected intra-peritoneally.
The MTD was defined as the dose resulting in 10-15% weight loss. Antitumour activity.
The murine colon tumour Colon 26 (Corbett, 1975) is maintained in our laboratory since 1983 (Peters, 1987 (Peters, , 1989 Van der Wilt, 1992) Time (day) In vivo antitumour activity Although the compounds were too toxic to administer according to the schedule used in the dosefinding study, conclusions can be drawn based on a single dose treatment of the colon26A bearing mice. The assumption was made that when even at this high dose no antitumour activity is present, it would be unlikely that lower doses at a schedule of qd7x2 would be able to produce an antitumour effect.
At their MTD, no antitumour effect was observed for the compounds 5, 7, 9, 10 and 11, i.e. the T/C (see fig. 12 to 14). Time (day) Figure 12 : Antitumour activity of compounds 5 and 9 against Colon 26A in Balb/C mice The compounds 6 and 8 (see fig. 13 and 14) showed clear antitumour activity after single dose administration (for 6 and 8, T/C equals respectively 0.51 and 0.42). The dose for both compounds was too toxic, however. Because of the promising results obtained with compound 6 at a single dose of 7.5 mg/kg (fig 13) , the dosis was decreased to 5 mg/kg in a second experiment ( fig. 14) in order to reduce the toxicity. The reduced dose also showed a antitumour effect which was less (T/C 0.81 but showed a comparable severe toxicity. 
Conclusions
The compounds 6 and 8 might be of interest for further antitumour activity studies. However, their severe toxicity makes the results difficult to interpret. An adapted formulation for administration of the compounds will be necessary for further evaluation of possible antitumour effects.
